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Abstract
Background—Cortical and subcortical gray matter (GM) atrophy may progress differently 
during the course of Parkinson's disease (PD). We delineated and compared the longitudinal 
pattern of these PD-related changes.
Methods—Structural MRIs and clinical measures were obtained from 76 PD with different 
disease durations and 70 Controls at baseline, 18- and 36-months. Both cortical and subcortical 
(putamen, caudate, and globus pallidus) GM volumes were obtained, compared, and associated 
with PD clinical measures at baseline. Their volumes and rates of change also were compared 
among Controls, PDs, and PD subgroups based on duration of illness [≤1 year (PDE), 1-5 years 
(PDM), and >5 years (PDL)].
Results—Compared to Controls, PD subjects displayed smaller cortical GM and striatal 
(putamen, caudate, ps≤0.001), volumes at baseline. Cortical GM volumes were negatively 
associated with disease duration at baseline, whereas striatal volumes were not. PD subjects 
demonstrated accelerated volume loss in cortical GM (p=0.006), putamen (p=0.034), and caudate 
(p=0.008) compared to Controls. Subgroup analyses demonstrated that accelerated cortical 
atrophy reached statistical significance in PD subjects with duration of illness 1-5 years (PDM, 
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ps<0.001) and the trend of accelerated atrophy seemed to persist until later stages, whereas striatal 
atrophy occurred in PD subjects with PDE (p=0.021 for putamen, p=0.005 for caudate) and PDM 
(p=0.002 for putamen, p=0.001 for caudate) that significantly slowed down in PDL (ps for PDL vs 
PDE or PDM: <0.01).
Conclusions—The pattern of GM loss in PD differs in cortical and subcortical regions, with 
striatal atrophy occurring earlier and extra-striatal cortical atrophy later.
Keywords
Parkinson's disease; brain atrophy; MRI; volume
Introduction
Parkinson's disease (PD) affects both motor and non-motor functions. Postmortem studies 
have shown focused pathology in the substantia nigra of the basal ganglia, as well as more 
diffuse Lewy pathology in extranigral brain regions.[1] Postmortem histologic studies are 
limited by the inability to capture dynamic changes as the disease unfolds in live patients. 
The exact pathoetiology and course of PD-related cell loss and its progression, however, 
remain unclear.
MR volumetric imaging can gauge in vivo macroscopic atrophy and assess both nigrostriatal 
and extranigral changes longitudinally. Extensive studies have demonstrated both cortical 
and subcortical gray matter (GM) atrophy in PD with both cross-sectional [2-4] and 
longitudinal designs [5-7] although some studies report no significant longitudinal volume 
changes in PD [8,9].
It is well-known that PD progression is not uniform over the disease course. Converging 
anatomical,[10] biochemical,[11] and clinical[12] evidence suggest the rate of motor and 
nigrostriatal pathological progression in PD is most rapid within the first five years of the 
diagnosis and then slows down or even plateaus, whereas extra-nigrostriatal and non-motor 
symptoms continue to progress during the remaining course of the disease [13]. Thus, GM 
changes in nigrostriatal and extra-nigrostriatal brain regions may evolve differently during 
the course of PD. This study investigated simultaneously cortical and subcortical GM 
changes and compared their atrophic patterns during the course of PD.
Methods
Subjects
A total of 76 PD and 70 matched control subjects (Controls; Table 1) were included in the 
study. PD subjects were recruited from a tertiary movement disorders clinic and Controls 
were recruited from the spouse population of the clinic or via IRB-approved recruitment 
materials posted in the local community. All subjects gave informed consent and were free 
of major/unstable medical issues such as liver, kidney, or thyroid abnormality, and 
deficiency of vitamin B12, or any cerebrovascular disease or neurological condition (other 
than PD). PD diagnosis was confirmed according to published criteria [14]. Disease duration 
was obtained from subject history with onset defined as the first diagnosis by a medical 
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professional. The study was conducted in accordance with the principles of the Declaration 
of Helsinki and reviewed and approved by the Penn State Hershey Institutional Review 
Board.
At baseline, subjects were screened using the Mini Mental Status Exam (MMSE) and only 
those with MMSE≥24 were enrolled. Olfactory function was evaluated using the University 
of Pennsylvania Smell Identification Test (UPSIT) [15] and depression assessed using the 
Hamilton depression scale [16]. Imaging and clinical data were captured at baseline, 18-, 
and 36-month follow-up visits, with 18- and 36-month follow-up visits occurring on average 
19.3±3.1 and 39.3±4.8 months after the baseline visit, respectively.
Motor function assessments
Unified PD Rating Scale part III-motor scores (UPDRS-III) [17] and Hoehn & Yahr (HY) 
stages were obtained for each PD subject in a practically defined “off” state after 
withholding PD medications overnight (~12 hr; [18]). The levodopa-equivalent daily dose 
(LEDD) was calculated according to published criteria [19].
MRI data acquisition
All subjects were scanned using a 3.0 Tesla MR Scanner (Trio, Siemens Magnetom, 
Erlangen, Germany, with an 8-channel phased array head coil) at baseline, 18-, and 36-
months. To avoid systematic bias, PD and Controls were scanned in an intermixed fashion 
throughout the longitudinal study. A magnetization-prepared rapid acquisition gradient echo 
sequence was used to obtain T1-weighted images with TR/TE=1540/2.34, FOV=256 mm × 
256 mm, matrix=256 × 256, slice thickness=1 mm (with no gap), slice number=176. Each 
MRI was inspected and deemed free of any significant structural abnormalities (tumor or 
vascular malformations).
Image processing and analysis
T1-weighted images were processed automatically using the longitudinal stream of 
FreeSurfer (version 5.1.0). This processing pipeline utilizes longitudinal image data from 
each time point to create an unbiased, within-subject template via a nonlinear surface-based 
registration procedure. Within-subject templates were used to initialize image processing 
(skull stripping, Talairach transforms, atlas registration, spherical surface maps, and 
parcellation) for subject scans at each visit. The final volumes of putamen, caudate, and 
globus pallidus are the sum of the left and right sides since there were no significant 
differences between sides (data not shown). The FreeSurfer longitudinal pipeline generated 
an average total intracranial volume (TIV, i.e., the sum of GM, WM, and CSF) across visits 
for each subject. Each region for individual subjects then was normalized by this TIV to 
calculate a percentage of TIV measurement that was included in the statistical analysis and 
presented in the results.
Statistical analysis
Gender, age, and education were compared using Fisher's exact test or two-tailed Student's t-
test as appropriate. Raw UPSIT scores were compared between groups using analysis of 
covariance (ANCOVA) with adjustment for age and gender. Clinical measures were 
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compared using two-sample t-tests (Controls and PDs) or analysis of variance (Controls and 
PD subgroups). The association between baseline volumes and clinical measures was 
assessed in PD subjects using Pearson's correlation.
For group and subgroup comparisons, baseline, 18-, and 36-month volumes were entered 
into a linear mixed-effects model to estimate baseline volume differences and the rate of GM 
atrophy for each region of interest (ROI). Age and gender also were entered as predictors in 
the mixed-effect models because of their known effects on brain volume and rate of brain 
atrophy [20]. Volume (normalized by TIV) at each visit was entered as the dependent 
variable and time elapsed since baseline visit was entered as the time variable. We assumed 
that the mean volume change was a linear function of time with intercept depending on 
linear and quadratic terms of baseline age (centered at 60 years), gender, and group (PD vs. 
Controls), and slope depending on the linear terms of age, gender, and group. A random 
intercept was included in the mixed-effects models to account for within-subject correlations 
of observations.
In order to evaluate the pattern of GM atrophy during the course of PD, the annual rate of 
change in both cortical and striatal regions was graphed (Figure S1) based on disease 
duration. In an effort to understand the stage-dependent volume changes in PD, PD subjects 
were sub-divided into three subgroups based upon the number of years since diagnosis [PDE 
(≤1yr), PDM (1-5yr), PDL (>5yr)], as we have done previously [21]. All statistical analyses 
were performed using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Demographic and study characteristics
PD and Control subjects did not differ significantly in gender or education at any visit (Table 
1). Overall, PD subjects showed significantly higher depression and lower UPSIT scores 
compared to Controls. PD subjects also were older than Controls at each time point.
At baseline, PD subjects displayed smaller total GM (p<0.001), cortical GM (p<0.001), 
putamen (p=0.001), and caudate (p=0.001) volumes compared to Controls (Table 2), with no 
significant difference observed in the globus pallidus. All three PD subgroups (PDE, PDM, 
and PDL subjects) had decreased total GM, cortical GM, and putamen volumes compared to 
Controls. PDM and PDL subgroups demonstrated decreased caudate, with PDE showing a 
trend (p=0.058). Within PD subgroups, there were no significant baseline volume 
differences.
From baseline, the dropout rate at 18-months was 18.5% for PD and 12.9% for Controls, 
respectively. Between the 18- and 36-month visits, the dropout rate for PDs and Controls 
was 19.4% and 7.2%, respectively. There were no significant differences between subjects 
remaining in the study and those who dropped out (data not shown).
Relationship of baseline volume and clinical measures in PD
Total and cortical GM volumes, but not striatum (caudate and putamen), were associated 
negatively with disease duration in PD subjects (Table 3). Cortical GM volume also was 
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correlated with UPDRS-III, UPSIT and MoCA scores, whereas caudate volume was 
correlated only with LEDD.
Longitudinal volume changes in PD and PD subgroups
Compared to Controls, PD subjects overall demonstrated significantly faster volume loss in 
total GM (p=0.002), cortical GM (p=0.006), putamen (p=0.034), and caudate (p=0.008; 
Table 4).
Visual inspection of Figure S1 indicates that whereas the most dynamic changes occurred 
within five years of diagnosis, the annual rate of volume loss remained at the rate of ~1% in 
total and cortical GM, even 15+ years following diagnosis. Statistically, cortical GM annual 
volume changes were significantly accelerated only in PDM subjects (p=0.001), and there 
were no significant differences between PDM and the other subgroups.
Conversely, annual volume changes in striatum (putamen and caudate) were accelerated only 
in PDE and PDM subjects compared to Controls (Table 4) but not in PDL. Indeed, annual 
volume changes appeared to plateau in these regions (hover ~0) 5-10 years after diagnosis 
(Figure S1), with significant differences comparing PDE and PDM to PDL subjects.
Discussion
The current study replicated past results indicating that GM atrophy occurs in PD. Most 
importantly, the current study provides the first in vivo evidence that cortical and subcortical 
GM have a different pattern and rate of atrophy during the course of PD. The results may 
reconcile past controversial findings relating GM changes associated with PD and guide the 
choice of more sensitive stage-dependent biomarkers for PD progression.
Cortical gray matter loss and its clinical and pathological implications
Previous imaging studies have reported mixed results in overall GM volumes in PD [2,8,9]. 
Several recent studies demonstrated [7,22,23], yet others failed to find [24,25], reduced 
cortical volume in PD. The exact reason for these discrepancies is not known but different 
methodologies (region of interest vs. voxel-based) may be one possible contributory factor. 
The current study employed a ROI-based and longitudinal design that allowed us to perform 
focused hypothesis testing. The finding of significant differences in both atrophy at baseline 
and rates of change longitudinally strengthens the argument for accelerated atrophy 
occurring in PD.
In our study, cortical GM volume was associated with MoCA and UPSIT scores. These 
results suggest that GM volume may reflect extra-nigral changes associated with PD. The 
findings are consistent with a recent report indicating that GM atrophy is associated with 
cognitive impairment and decline in PD [26] and with other studies linking GM changes to 
cognitive performance [3,4]. Moreover, they are congruent with reduced olfactory function 
in PD being related to reduced volume in piriform and orbitofrontal cortices [27].
It is well established that the striatum makes significant connections with cortical areas 
through striato-thalamo-cortical pathways and reciprocal, topographic projections via 
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cortico-striatal circuits [28]. Our finding of a significant association between cortical GM 
changes and UPDRS-III scores is supportive of the hypothesis that cortical GM changes also 
may capture at least part of nigrostriatal pathologies. Future studies interrogating the 
relationship between detailed motor/non-motor dysfunctions and refined cortical regions of 
interest in PD are warranted, and may yield knowledge on the neuropathological 
underpinning of different PD-related symptomologies.
As expected, cortical GM volumes were related to disease duration. Visual inspection of the 
time course of GM volume changes and PD subgroup analyses suggested that the 
accelerated cortical GM seems to be most significant one year after PD diagnosis, and the 
accelerated rate seems to maintain thereafter at 1% per year (Figure S1). This finding is 
consistent with Braak staging, which demonstrated that diffuse cortical involvement of PD 
pathology probably does not occur until later disease stages [1]. Cortical GM changes may 
be useful to gauge pathological changes in later-stage patients.
Striatal volume loss and its clinical and pathological implications
The striatum (caudate and putamen) composes the primary input stage of the basal ganglia 
and receives direct projections from dopamine neurons of the substantia nigra, whereas the 
globus pallidus is regulated indirectly by the substantia nigra pars compacta via the striatum 
[28]. Basal ganglia structures may undergo structural changes due to nigrostriatal 
denervation. In this study, PD subjects (and subgroups) displayed putamen and caudate 
atrophy, with no significant change in the globus pallidus, compared to Controls. These 
results are consistent with several prior studies [26,29] but in contrast to a recent study that 
reported no change in basal ganglia volumes in cognitively-intact PD subjects [7]. The 
current data, however, support the hypothesis that nigral denervation affects the structure of 
immediate downstream targets. Consistent with this, the current study also found that 
caudate volume is significantly associated with LEDD, a measurement reflecting striatal 
dopamine deficits. In addition, positive correlations also were found between putamen 
volume and MoCA scores. These results underscore the function of striatal structures in 
cognition [30].
Interestingly, striatal atrophy was not correlated with duration of illness. These results are 
consistent with previous clinical and radioligand studies that have shown dopamine cell loss 
in PD may not be linear throughout PD progression [31,32]. In order to understand the 
potential stage dependent GM changes, we subdivided PD group to three subgroups based 
on the following rationale: 1) The upper limit of disease duration of one year was chosen to 
define a group of PDE subjects that had not received extended treatment. 2) PDL was defined 
as those PD subjects having at least five years of disease duration because nigrostriatal 
terminal labeling is known to reach a floor after approximately five years [33], although 
there are some data suggesting that nigral cell death may continue [34]. 3) Clinically, 
dyskinesias, cognitive decline, and dopamine-non-responsive symptoms tend to be more 
prominent after the first five years (“honeymoon” phase) [35]. 4) Lastly, these subgroup 
categorizations also happen to yield relatively balanced subgroup sample sizes, which is 
powerful for equivalence testing [33,36,37]. Consistent with our expectations, the highest 
rates of striatal atrophy were observed in patients during the first five years of disease (PDE 
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and PDM) and then plateaued thereafter (Figure S1). These temporal relations of our study 
lend further support to the hypothesis that basal ganglia atrophy may be the consequence of 
nigrostriatal dopamine denervation, rather than an independent pathology (such as new 
spreading Lewy pathology). We recognize that despite our rationale, the selection of 
subgroups based upon disease duration might seem arbitrary, so we repeated our analyses 
using HY stage, yielding similar results (data not presented). Together, our results support 
the notion that cortical and subcortical GM atrophy have different patterns and are stage-
dependent.
Limitations
Despite a number of strengths, the study has several limitations. The number of subjects 
included in the study was moderately large for a longitudinal imaging study, but small 
compared to PD-related epidemiological studies. Moreover, because most PD subjects 
included in the study were within ~10 years of diagnosis, we may not have captured disease 
changes that may arise in very late stages of disease. The subcortical volume analysis was 
focused on striatal and pallidal regions, and thus may have missed important changes 
associated with PD in other brain areas. In addition, cortical GM was not parcellated into 
refined regions of interests to interrogate their individual trajectories or clinical implications.
Summary
In summary, the current study not only confirmed GM atrophy in PD, but demonstrated 
different patterns of cortical and subcortical atrophy during PD. Further studies are 
warranted to investigate the potential of using striatal atrophy to gauge early nigrostriatal 
denervation-related changes and cortical GM volumes to monitor later, global pathological 
processes and their clinical implications in PD.
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Acknowledgements
We express gratitude to all of the participants who volunteered for this study and study personnel who contributed 
to its success. This work was supported in part by the National Institute of Neurological Disease and Stroke 
(NS060722 and NS082151 to XH), the Hershey Medical Center General Clinical Research Center (National Center 
for Research Resources, Grant UL1 RR033184 that is now at the National Center for Advancing Translational 
Sciences, Grant UL1 TR000127), and the PA Department of Health Tobacco CURE Funds. All analyses, 
interpretations, and conclusions are those of the authors and not the research sponsors.
Reference List
1. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology 
related to sporadic Parkinson's disease. Neurobiol Aging. Mar; 2003 24(2):197–211. [PubMed: 
12498954] 
2. Melzer TR, Watts R, MacAskill MR, Pitcher TL, Livingston L, Keenan RJ, et al. Grey matter 
atrophy in cognitively impaired Parkinson's disease. Journal of neurology, neurosurgery, and 
psychiatry. Mar; 2012 83(2):188–94.
3. Martin WR, Wieler M, Gee M, Camicioli R. Temporal lobe changes in early, untreated Parkinson's 
disease. Mov Disord. Oct 15; 2009 24(13):1949–54. [PubMed: 19606493] 
Lewis et al. Page 7
J Neurol. Author manuscript; available in PMC 2017 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
4. Gerrits NJ, van der Werf YD, Hofman M, Foncke EM, Klein M, Berendse HW, et al. Gray matter 
differences contribute to variation in cognitive performance in Parkinson's disease. Eur J Neurol. 
Feb; 2014 21(2):245–52. [PubMed: 24112523] 
5. Hu MT, White SJ, Chaudhuri KR, Morris RG, Bydder GM, Brooks DJ. Correlating rates of cerebral 
atrophy in Parkinson's disease with measures of cognitive decline. J Neural Transm. 2001; 108(5):
571–80. [PubMed: 11459077] 
6. Ibarretxe-Bilbao N, Junque C, Segura B, Baggio HC, Marti MJ, Valldeoriola F, et al. Progression of 
cortical thinning in early Parkinson's disease. Mov Disord. Dec; 2012 27(14):1746–53. [PubMed: 
23124622] 
7. Mak E, Su L, Williams GB, Firbank MJ, Lawson RA, Yarnall AJ, et al. Baseline and longitudinal 
grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain. Oct; 2015 
138(Pt 10):2974–86. [PubMed: 26173861] 
8. Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC. Longitudinal MRI in progressive 
supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain. Apr; 2006 
129(Pt 4):1040–9. [PubMed: 16455792] 
9. Camicioli R, Sabino J, Gee M, Bouchard T, Fisher N, Hanstock C, et al. Ventricular dilatation and 
brain atrophy in patients with Parkinson's disease with incipient dementia. Mov Disord. Jul; 2011 
26(8):1443–50. [PubMed: 21442661] 
10. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 
Oct; 1991 114(Pt 5):2283–301. [PubMed: 1933245] 
11. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the 
syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. 
J Neurol Sci. Dec; 1973 20(4):415–55. [PubMed: 4272516] 
12. Schulzer M, Lee CS, Mak EK, Vingerhoets FJ, Calne DB. A mathematical model of pathogenesis 
in idiopathic parkinsonism. Brain. Jun; 1994 117(Pt 3):509–16. [PubMed: 8032861] 
13. Halliday GM, McCann H. The progression of pathology in Parkinson's disease. Ann N Y Acad Sci. 
Jan.2010 1184:188–95. [PubMed: 20146698] 
14. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. Jan; 1999 
56(1):33–9. [PubMed: 9923759] 
15. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification 
Test: a standardized microencapsulated test of olfactory function. Physiol Behav. Mar; 1984 32(3):
489–502. [PubMed: 6463130] 
16. HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. Feb.1960 23:56–62. 
[PubMed: 14399272] 
17. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement 
Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-
UPDRS): scale presentation and clinimetric testing results. Mov Disord. Nov 15; 2008 23(15):
2129–70. [PubMed: 19025984] 
18. Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, Freeman T, et al. Core assessment program 
for intracerebral transplantations (CAPIT). Mov Disord. 1992; 7(1):2–13. [PubMed: 1557062] 
19. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose 
equivalency reporting in Parkinson's disease. Mov Disord. Nov 15; 2010 25(15):2649–53. 
[PubMed: 21069833] 
20. Ruigrok AN, Salimi-Khorshidi G, Lai MC, Baron-Cohen S, Lombardo MV, Tait RJ, et al. A meta-
analysis of sex differences in human brain structure. Neurosci Biobehav Rev. Feb.2014 39:34–50. 
[PubMed: 24374381] 
21. Du G, Lewis MM, Sen S, Wang J, Shaffer ML, Styner M, et al. Imaging nigral pathology and 
clinical progression in Parkinson's disease. Mov Disord. Nov; 2012 27(13):1636–43. [PubMed: 
23008179] 
22. Rosenberg-Katz K, Herman T, Jacob Y, Giladi N, Hendler T, Hausdorff JM. Gray matter atrophy 
distinguishes between Parkinson disease motor subtypes. Neurology. Apr 16; 2013 80(16):1476–
84. [PubMed: 23516323] 
Lewis et al. Page 8
J Neurol. Author manuscript; available in PMC 2017 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
23. Fioravanti V, Benuzzi F, Codeluppi L, Contardi S, Cavallieri F, Nichelli P, et al. MRI correlates of 
Parkinson's disease progression: a voxel based morphometry study. Parkinsons Dis. 2015; 
2015:378032. [PubMed: 25628916] 
24. Weintraub D, Dietz N, Duda JE, Wolk D, Doshi J, Xie SX, et al. Alzheimer's disease pattern of 
brain atrophy predicts cognitive decline in Parkinson's disease. Brain : a journal of neurology. Jan; 
2012 135(Pt 1):170–80. [PubMed: 22108576] 
25. Kato S, Watanabe H, Senda J, Hirayama M, Ito M, Atsuta N, et al. Widespread cortical and 
subcortical brain atrophy in Parkinson's disease with excessive daytime sleepiness. J Neurol. Feb; 
2012 259(2):318–26. [PubMed: 21850388] 
26. Hanganu A, Bedetti C, Degroot C, Mejia-Constain B, Lafontaine AL, Soland V, et al. Mild 
cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson's 
disease longitudinally. Brain. Apr; 2014 137(Pt 4):1120–9. [PubMed: 24613932] 
27. Lee EY, Eslinger PJ, Du G, Kong L, Lewis MM, Huang X. Olfactory-related cortical atrophy is 
associated with olfactory dysfunction in Parkinson's disease. Mov Disord. Aug; 2014 29(9):1205–
8. [PubMed: 24482154] 
28. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits 
linking basal ganglia and cortex. Annu Rev Neurosci. 1986; 9:357–81. [PubMed: 3085570] 
29. Peran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, Peppe A, et al. Magnetic resonance 
imaging markers of Parkinson's disease nigrostriatal signature. Brain. Aug 23.2010 
30. Middleton FA, Strick PL. Basal ganglia and cerebellar loops: motor and cognitive circuits. Brain 
Res Brain Res Rev. Mar; 2000 31(2-3):236–50. [PubMed: 10719151] 
31. Lee CS, Schulzer M, Mak EK, Snow BJ, Tsui JK, Calne S, et al. Clinical observations on the rate 
of progression of idiopathic parkinsonism. Brain. Jun; 1994 117(Pt 3):501–7. [PubMed: 8032860] 
32. Rossi C, Frosini D, Volterrani D, De FP, Unti E, Nicoletti V, et al. Differences in nigro striatal 
impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study. 
Eur J Neurol. Apr; 2010 17(4):626–30. [PubMed: 20050904] 
33. Maetzler W, Liepelt I, Berg D. Progression of Parkinson's disease in the clinical phase: potential 
markers. Lancet Neurol. Dec; 2009 8(12):1158–71. [PubMed: 19909914] 
34. Perlmutter JS, Norris SA. Neuroimaging biomarkers for Parkinson disease: facts and fantasy. Ann 
Neurol. Dec; 2014 76(6):769–83. [PubMed: 25363872] 
35. Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL. Limitations of current 
Parkinson's disease therapy. Ann Neurol. 2003; 53(Suppl 3):S3–12. [PubMed: 12666094] 
36. Lee CS, Schulzer M, Mak EK, Snow BJ, Tsui JK, Calne S, et al. Clinical observations on the rate 
of progression of idiopathic parkinsonism. Brain. Jun; 1994 117(Pt 3):501–7. [PubMed: 8032860] 
37. Lee CS, Schulzer M, Fuente-Fernandez R, Mak E, Kuramoto L, Sossi V, et al. Lack of regional 
selectivity during the progression of Parkinson disease: implications for pathogenesis. Arch 
Neurol. Dec; 2004 61(12):1920–5. [PubMed: 15596613] 
Lewis et al. Page 9
J Neurol. Author manuscript; available in PMC 2017 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Lewis et al. Page 10
Table 1
Demographic and clinical characteristics of participants at baseline, 18 months, and 36 months.
Control PD PDE PDM PDL P-values1 P-values2
Baseline
N Subjects (F,M) 70 (36, 34) 76 (29, 47) 22 (11, 11) 27 (10, 17) 27 (8, 19) 0.134* 0.207*
Age (y) 59.8 ± 7.7 63.3 ± 8.4 61.5 ± 9.8 61.4 ± 6.9 66.6 ± 7.8 0.011 0.008
Education (y) 16.6 ± 2.8 15.9 ± 2.7 16.1 ± 2.4 15.8 ± 2.4 15.9 ± 3.3 0.135 0.163
MMSE 29.5 ± 0.9 29.1 ± 1.1 29.3 ± 1.2 29.1 ± 1.3 29.0 ± 0.9 0.121 0.124
HAM-D 3.8 ± 2.5 7.7 ± 4.5 7.3 ± 4.4 7.2 ± 3.7 8.4 ± 5.3 <0.0001 <0.0001
UPSIT 34.1 ± 5.3 21.3 ± 7.4 23.9 ± 7.6 20.6 ± 8.3 20.1 ± 5.5 <0.0001 <0.0001
Clinical Measures
    Disease duration (y) na 4.9 ± 5.5 0.4 ± 0.3 2.5 ± 1.2 11.0 ± 5.0 - 0.0001
    LEDD (mg) na 557 ± 458 247 ± 203 474 ± 361 893 ± 484 - <0.0001
    UPDRS-III na 22.5 ± 14.3 13.1 ± 7.2 22.6 ± 11.1 31.2 ± 17.3 - 0.002
    HY Stage na 1.8 ± 0.7 1.4 ± 0.6 1.7 ± 0.7 2.2 ± 0.6 - <0.0001
18 months
N Subjects (F,M) 61 (31, 30) 62 (27, 35) 18 (10, 8) 21 (10, 11) 23 (7, 16) 0.472* 0.329*
Age (y) 61.3 ± 7.8 64.9 ± 8.4 62.7 ± 9.4 63.2 ± 7.1 68.1 ± 8.0 0.017 0.002
Education (y) 16.5 ± 2.9 15.8 ± 2.7 16.2 ± 2.4 15.6 ± 2.3 15.7 ± 3.4 0.140 0.112
Clinical Measures
    Disease duration (y) na 6.6 ± 5.5 2.1 ± 0.4 4.1 ± 1.2 12.3 ± 5.1 - <0.0001
    LEDD (mg) na 767 ± 491 444 ± 223 709 ± 438 1043 ± 528 - 0.0001
    UPDRS-III na 26.3 ± 19.7 14.8 ± 7.1 26.4 ± 21.3 37.8 ± 20.6 - <0.0001
    HY Stage na 2.2 ± 1.0 1.6 ± 0.7 2.2 ± 0.9 2.6 ± 1.1 - <0.0001
36 months
N Subjects (F,M) 56 (30, 26) 50 (24, 26) 16 (8, 8) 18 (9, 9) 16 (7, 9) 0.697* 0.956*
Age (y) 63.0 ± 7.8 66.4 ± 7.9 66.7 ± 9.5 64.3 ± 6.2 68.6 ± 7.6 0.027 0.024
Education (y) 16.4 ± 2.8 15.7 ± 2.7 16.3 ± 2.5 15.3 ± 2.3 15.5 ± 3.3 0.206 0.139
Clinical Measures
    Disease duration (y) na 7.8 ± 5.3 3.7 ± 0.4 5.6 ± 1.2 14.5 ± 4.1 - 0.008
    LEDD (mg) na 911 ± 604 685 ± 250 745 ± 509 1304 ± 738 - 0.009
    UPDRS-III na 32.7 ± 18.6 22.0 ± 9.0 33.6 ± 19.9 46.8 ± 18.1 - <0.0001
    HY Stage na 1.9 ± 0.6 1.7 ± 0.7 2.0 ± 0.5 2.1 ± 0.8 - <0.0001
Measurements presented as mean ± SD unless otherwise indicated.
Abbreviations: HY: Hoehn-Yahr; HAM-D: Hamilton Depression score; MMSE: Mini-Mental Status Exam; LEDD: levodopa daily equivalent 
dosage; UPDRS: Unified Parkinson's Disease Rating Scale; UPSIT: University of Pittsburgh Smell Identification Test.
1
P-values for comparisons between all PD and Control subjects using two-sample t-tests.
2
P-values of ANOVA across PD subgroups (and Controls as appropriate).
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*
P-values obtained using Fisher's exact test.
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Table 2
Baseline volume estimate data of Controls, PDs, and PD subgroups.
Total GM Cortical GM Putamen Caudate GP
Baseline Volumes of PD and its subgroups (mean ±SE)
Control, N=70 414.8±2.6 305.3±2.1 3.254±0.044 2.370±0.030 0.890±0.019
PD, N=76 402.5±2.8 294.5±2.2 3.029±0.047 2.248±0.032 0.908±0.020
PDE, N=22 400.6±4.5 292.6±3.6 2.978±0.076 2.268±0.030 0.930±0.033
PDM, N=27 405.1±3.8 296.8±3.0 3.068±0.064 2.257±0.043 0.900±0.027
PDL, N=27 400.3±4.4 292.6±3.5 3.020±0.074 2.214±0.050 0.899±0.032
P-values for group comparisons
Control vs. PD <0.001 <0.001 0.001 0.001 0.450
Control vs. PDE 0.004 0.001 0.001 0.058 0.245
Control vs. PDM 0.032 0.018 0.014 0.024 0.781
Control vs. PDL 0.002 0.001 0.004 0.003 0.809
PDE vs. PDM 0.409 0.349 0.340 0.868 0.443
PDE vs. PDL 0.959 0.999 0.656 0.394 0.433
PDM vs. PDL 0.364 0.332 0.596 0.477 0.986
The volume estimate for each subject was expressed relative to baseline total intracranial volume (TIV) for that subject, with units per mille. 
Baseline volumes were compared among groups using longitudinal mixed-effects analysis (see Methods for details). P values are bolded for those 
reaching statistical significance.
Abbreviations: GM = gray matter; GP = globus pallidus; PD = Parkinson's disease; PDE = early stage Parkinson's disease; PDM = middle stage 
Parkinson's disease; PDL = late stage Parkinson's disease. Disease stage was defined based on disease duration (see Methods for details).
J Neurol. Author manuscript; available in PMC 2017 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Lewis et al. Page 13
Ta
bl
e 
3
Co
rre
la
tio
ns
 b
et
w
ee
n 
vo
lu
m
e 
an
d 
cl
in
ic
al
 m
ea
su
re
s i
n 
PD
 su
bje
cts
 at
 ba
sel
ine
.
D
ise
as
e 
du
ra
tio
n
U
PD
R
S-
II
I
LE
D
D
M
oC
A
H
am
D
U
PS
IT
r
p-
va
lu
e
r
p-
va
lu
e
r
p-
va
lu
e
r
p-
va
lu
e
r
p-
va
lu
e
r
p-
va
lu
e
To
ta
l G
M
−
0.
30
4
0.
00
8
−
0.
21
9
0.
05
7
−
0.
19
3
0.
09
5
0.
37
0
0.
00
1
−
0.
03
8
0.
75
1
0.
22
1
0.
06
6
C
or
tic
al
 G
M
−
0.
31
6
0.
00
5
−
0.
23
1
0.
04
5
−
0.
20
7
0.
07
2
0.
38
4
<
0.
00
1
−
0.
02
2
0.
85
3
0.
24
2
0.
04
4
Pu
ta
m
en
−
0.
15
7
0.
17
7
−
0.
07
4
0.
55
0
−
0.
07
0
0.
55
0
0.
28
0
0.
01
6
0.
00
4
0.
97
3
−
0.
13
4
0.
26
7
C
au
da
te
−
0.
15
6
0.
17
7
−
0.
10
3
0.
37
4
−
0.
30
4
0.
00
8
0.
21
3
0.
06
9
−
0.
02
9
0.
80
7
0.
01
6
0.
89
5
G
lo
bu
s 
pa
lli
du
s
−
0.
00
1
0.
99
3
−
0.
02
0
0.
86
1
−
0.
05
3
0.
64
8
0.
00
4
0.
97
6
−
0.
12
5
0.
29
6
−
0.
08
1
0.
50
3
Va
lu
es
 re
pr
es
en
t t
he
 P
ea
rs
on
's 
co
rre
la
tio
n 
co
ef
fic
ie
nt
 (r
), w
ith
 th
e a
sso
cia
ted
 p-
va
lu
e 
to
 th
e 
rig
ht
.
B
ol
d 
te
x
t r
ep
re
se
nt
s s
ig
ni
fic
an
t c
or
re
la
tio
ns
.
A
bb
re
v
ia
tio
ns
: G
M
 =
 G
ra
y 
m
at
te
r, 
H
am
D
 =
 H
am
ilt
on
 D
ep
re
ss
io
n 
Sc
al
e,
 L
ED
D
 =
 L
ev
o
do
pa
 e
qu
iv
al
en
t d
ai
ly
 d
os
ag
e,
 M
oC
A
 =
 M
on
tre
al
 C
og
ni
tiv
e 
A
ss
es
sm
en
t, 
U
PD
RS
-II
I =
 U
ni
fie
d 
Pa
rk
in
so
n's
 D
ise
as
e 
R
at
in
g 
Sc
al
e 
– 
m
ot
or
 sc
or
e,
 U
PS
IT
 =
 U
ni
v
er
sit
y 
of
 P
itt
sb
u
rg
h 
Sm
el
l I
de
nt
ifi
ca
tio
n 
sc
or
e
J Neurol. Author manuscript; available in PMC 2017 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Lewis et al. Page 14
Table 4
Annual rates of change estimate data over 36 months in Controls, PDs, and PD subgroups.
Total GM Cortical GM Putamen Caudate GP
Estimates of annual rates of volume changes (mean±SE):
Control, N=70 −2.26±0.35 −1.81±0.30 −0.015±0.004 −0.021±0.005 0.001±0.002
PD, N=76 −3.71±0.38 −2.86±0.32 −0.027±0.005 −0.037±0.005 0.002±0.002
PDE, N=22 −3.12±0.61 −2.33±0.52 −0.032±0.007 −0.044±0.008 −0.003±0.003
PDM, N=27 −4.55±0.53 −3.48±0.45 −0.037±0.006 −0.045±0.007 0.003±0.003
PDL, N=27 −3.02±0.58 −2.44±0.50 −0.008±0.007 −0.019±0.007 0.004±0.003
P values of group comparisons:
Control vs. PD 0.002 0.006 0.034 0.008 0.802
Control vs. PDE 0.136 0.278 0.021 0.005 0.205
Control vs. PDM <0.001 0.001 0.002 0.001 0.434
Control vs. PDL 0.166 0.186 0.443 0.852 0.374
PDE vs. PDM 0.064 0.081 0.618 0.864 0.097
PDE vs. PDL 0.896 0.870 0.010 0.011 0.074
PDM vs. PDL 0.042 0.101 0.002 0.006 0.918
Control, PD, and PD subgroup annual rates of change estimates for each group or subgroup. The annual volume change for each subject was 
expressed relative to total intracranial volume (TIV) for that subject, with units per mille. Annual rates of change were compared among groups 
using longitudinal mixed-effects analysis (see Methods for details), with decreasing numbers of subjects at the 18- and 36 month visits (see Table 1 
for subject sample sizes at the different time points). P values are listed for the relevant comparisons, with those reaching statistical significance 
bolded.
Abbreviations: GM = gray matter; GP = globus pallidus; PD = Parkinson's disease; PDE = early stage Parkinson's disease; PDM = middle stage 
Parkinson's disease; PDL = late stage Parkinson's disease. Disease stage was defined based on disease duration (see Methods for details).
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